This list is an analysis based on recent market events. It's not an investment recommendation.
About
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
The current price of J8P.F is €1.07 EUR — it has increased by +0.19% in the past 24 hours. Watch Cinclus Pharma AB stock price performance more closely on the chart.
What is Cinclus Pharma AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cinclus Pharma AB stocks are traded under the ticker J8P.F.
Is Cinclus Pharma AB stock price growing?▼
J8P.F stock has fallen by -30.42% compared to the previous week, the month change is a -29.5% fall, over the last year Cinclus Pharma AB has showed a +11.16% increase.
What is Cinclus Pharma AB market cap?▼
Today Cinclus Pharma AB has the market capitalization of 49.61M
What is Cinclus Pharma AB revenue for the last year?▼
Cinclus Pharma AB revenue for the last year amounts to 799,539.43 EUR.
What is Cinclus Pharma AB net income for the last year?▼
J8P.F net income for the last year is -29.4M EUR.
How many employees does Cinclus Pharma AB have?▼
As of April 29, 2026, the company has 21 employees.
In which sector is Cinclus Pharma AB located?▼
Cinclus Pharma AB operates in the Other sector.
When did Cinclus Pharma AB complete a stock split?▼
Cinclus Pharma AB has not had any recent stock splits.
Where is Cinclus Pharma AB headquartered?▼
Cinclus Pharma AB is headquartered in Stockholm, Sweden.